Teva: Weltruza Approval Deepens Teva's Neurology Expertise and Doubles Down on Long-Term Strategy
Teva announced the US Food and Drug Administration approval of Weltruza (long-acting olanzapine). The once-monthly subcutaneous injection requires neither loading dose nor post-injection monitoring and comes in three strengths. Teva shares are up 6% intraday Oct. 9 on the news.